Vincent H. Wu

Vincent H. Wu

Auto-generated profile, based on publicly available information

Vincent H. Wu

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
TSTakuya Sekine
Takuya Sekine
APAndré Perez-Potti
André Perez-Potti
SNSon Nguyen
Son Nguyen
JGJean-Baptiste Gorin
Jean-Baptiste Gorin
VWVincent H. Wu
Vincent H. Wu
MBMarcus Buggert
Marcus Buggert
CD8+ T cell exhaustion is a hallmark of many cancers and chronic infections. In mice, T cell factor 1 (TCF-1) maintains exhausted CD8+ T cell responses, whereas thymocyte selection-associated HMG box (TOX) is required for the epigenetic remodeling and survival of exhausted CD8+ T cells. However, it has remained unclear to what extent these transcription factors play analogous roles in humans. In this study, we mapped the expression of TOX and TCF-1 as a function of differentiation and specificity in the human CD8+ T cell landscape. Here, we demonstrate that circulating TOX+ CD8+ T cells exist in most humans, but that TOX is not exclusively associated with exhaustion. Effector memory CD8+ T cells generally expressed TOX, whereas naive and early-differentiated memory CD8+ T cells generally expressed TCF-1. Cytolytic gene and protein expression signatures were also defined by the expression of TOX. In the context of a relentless immune challenge, exhausted HIV-specific CD8+ T cells commonly expressed TOX, often in clusters with various activation markers and inhibitory receptors, and expressed less TCF-1. However, polyfunctional memory CD8+ T cells specific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV) also expressed TOX, either with or without TCF-1. A similar phenotype was observed among HIV-specific CD8+ T cells from individuals who maintained exceptional immune control of viral replication. Collectively, these data demonstrate that TOX is expressed by most circulating effector memory CD8+ T cell subsets and not exclusively linked to exhaustion.

18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SNSon Nguyen
Son Nguyen
CDClaire Deleage
Claire Deleage
SDSamuel Darko
Samuel Darko
ARAmy Ransier
Amy Ransier
DTDuc P. Truong
Duc P. Truong
MBMichael R. Betts
Michael R. Betts
Elite control of HIV replication is linked to polyfunctional lymphoid CD8 + T cells that lack overt cytolytic activity and home to B cell follicles.

19 December 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
VWVincent H. Wu
Vincent H. Wu
JNJayme M. L. Nordin
Jayme M. L. Nordin
SNSon Nguyen
Son Nguyen
JJJaimy Joy
Jaimy Joy
FMFelicity Mampe
Felicity Mampe
MBMichael R. Betts
Michael R. Betts
Understanding the complexity of the long-lived HIV reservoir during antiretroviral therapy (ART) remains a considerable impediment in research towards a cure for HIV. To address this, we developed a single-cell strategy to precisely define the unperturbed peripheral blood HIV-infected memory CD4+ T cell reservoir from ART-treated people living with HIV (ART-PLWH) via the presence of integrated accessible proviral DNA in concert with epigenetic and cell surface protein profiling. We identified profound reservoir heterogeneity within and between ART-PLWH, characterized by new and known surface markers within total and individual memory CD4+ T cell subsets. We further uncovered new epigenetic profiles and transcription factor motifs enriched in HIV-infected cells that suggest infected cells with accessible provirus, irrespective of reservoir distribution, are poised for reactivation during ART treatment. Together, our findings reveal the extensive inter- and intrapersonal cellular heterogeneity of the HIV reservoir, and establish an initial multiomic atlas to develop targeted reservoir elimination strategies.

10 December 2020 in Cell
Verified
Journal Article
Closed access
MBMarcus Buggert
Marcus Buggert
LVLaura A. Vella
Laura A. Vella
SNSon Nguyen
Son Nguyen
VWVincent H. Wu
Vincent H. Wu
ZCZeyu Chen
Zeyu Chen
MBMichael R. Betts
Michael R. Betts

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
VWVincent H. Wu
Vincent H. Wu
RSRobert Smith
Robert Smith
SMSara Masoum
Sara Masoum
DRDana N. Raugi
Dana N. Raugi
SBSelly Ba
Selly Ba
GGGeoffrey S. Gottlieb
Geoffrey S. Gottlieb
There is a pressing need to identify more effective antiretroviral drugs for HIV-2 treatment. Here, we show that the investigational compound MK-8591 (4′-ethynyl-2-fluoro-2′-deoxyadenosine [EFdA]) is highly active against group A and B isolates of HIV-2; 50% effective concentrations [EC50] for HIV-2 were, on average, 4.8-fold lower than those observed for HIV-1. MK-8591 also retains potent activity against multinucleoside-resistant HIV-2 mutants (EC50≤ 11 nM). These data suggest that MK-8591 may have antiviral activity in HIV-2-infected individuals.

15 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
VWVincent H. Wu
Vincent H. Wu
CNChristopher L. Nobles
Christopher L. Nobles
LKLeticia Kuri-Cervantes
Leticia Kuri-Cervantes
KMKevin McCormick
Kevin McCormick
JEJohn K. Everett
John K. Everett
MBMichael R. Betts
Michael R. Betts
The integration of HIV DNA into the host genome contributes to lifelong infection in most individuals. Few studies have examined integration in lymphoid tissue, where HIV predominantly persists before and after antiretroviral treatment (ART). Of particular interest is whether integration site distributions differ between infection stages with paired blood and tissue comparisons. Here, we profiled HIV integration site distributions in sorted memory, tissue-resident, and/or follicular helper CD4 + T cell subsets from paired blood and lymphoid tissue samples from acute, chronic, and ART-treated individuals. We observed minor differences in the frequency of nonintronic and nondistal intergenic sites, varying with tissue and residency phenotypes during ART. Genomic and epigenetic annotations were generally similar. Clonal expansion of cells marked by identical integration sites was detected, with increased detection in chronic and ART-treated individuals. However, overlap between or within CD4 + T cell subsets or tissue compartments was only observed in 8 unique sites of the 3540 sites studied. Together, these findings suggest that shared integration sites between blood and tissue may, depending on the tissue site, be the exception rather than the rule and indicate that additional studies are necessary to fully understand the heterogeneity of tissue-sequestered HIV reservoirs.